197 related articles for article (PubMed ID: 28744159)
1. Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.
Zeng ZH; Chen JF; Li YX; Zhang R; Xiao LF; Meng XY
Cancer Manag Res; 2017; 9():287-298. PubMed ID: 28744159
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
3. Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
Yang G; Geng C; Jian Y; Zhou H; Chen W
Adv Ther; 2022 Aug; 39(8):3799-3834. PubMed ID: 35771352
[TBL] [Abstract][Full Text] [Related]
4. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
[TBL] [Abstract][Full Text] [Related]
5. Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.
Liu X; Chen J; He YA; Meng X; Li K; He CK; Liu S
Onco Targets Ther; 2017; 10():121-128. PubMed ID: 28053546
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.
Moreau P; Hulin C; Zweegman S; Hashim M; Hu Y; Heeg B; de Boer C; Vanquickelberghe V; Kampfenkel T; He J; Lam A; Cote S; Sonneveld P
EJHaem; 2021 Feb; 2(1):66-80. PubMed ID: 35846097
[TBL] [Abstract][Full Text] [Related]
7. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Rosiñol L; Hebraud B; Oriol A; Colin AL; Ríos Tamayo R; Hulin C; Blanchard MJ; Caillot D; Sureda A; Hernández MT; Arnulf B; Mateos MV; Macro M; San-Miguel J; Belhadj K; Lahuerta JJ; Garelik MB; Bladé J; Moreau P
Front Oncol; 2023; 13():1197340. PubMed ID: 38023148
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Ricci D; Cakana A; Enny C; Feng H; van de Velde H; Harousseau JL
J Clin Oncol; 2013 Jan; 31(2):247-55. PubMed ID: 23091109
[TBL] [Abstract][Full Text] [Related]
10. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.
Sonneveld P; Mateos MV; Alegre A; Facon T; Hulin C; Hashim M; Vincken T; Kampfenkel T; Cote S; He J; Lam A; Moreau P
EJHaem; 2020 Nov; 1(2):481-488. PubMed ID: 35845005
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
15. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S
Cancer; 2013 Dec; 119(23):4119-28. PubMed ID: 24005889
[TBL] [Abstract][Full Text] [Related]
18. Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.
Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; Mateos MV; Attal M
JAMA Oncol; 2018 Oct; 4(10):1389-1397. PubMed ID: 30098165
[TBL] [Abstract][Full Text] [Related]
19. Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Sauer S; Kriegsmann K; Nientiedt C; Schmitt A; Müller-Tidow C; Raab MS; Kauer J
Transfus Med Hemother; 2023 Oct; 50(5):371-381. PubMed ID: 37936633
[TBL] [Abstract][Full Text] [Related]
20. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.
Hungria VT; Crusoé EQ; Maiolino A; Bittencourt R; Fantl D; Maciel JF; Pessoa de Magalhaes RJ; Almeida MS; Cury P; Hisgashi F; Peres AL; Chiattone CS
Ann Hematol; 2016 Jan; 95(2):271-8. PubMed ID: 26518211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
